ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVO Advanced Oncotherapy Plc

1.925
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.925 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -29.49M -0.0549 -0.35 10.32M
Advanced Oncotherapy Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker AVO. The last closing price for Advanced Oncotherapy was 1.93p. Over the last year, Advanced Oncotherapy shares have traded in a share price range of 1.875p to 8.50p.

Advanced Oncotherapy currently has 537,481,209 shares in issue. The market capitalisation of Advanced Oncotherapy is £10.32 million. Advanced Oncotherapy has a price to earnings ratio (PE ratio) of -0.35.

Advanced Oncotherapy Share Discussion Threads

Showing 3351 to 3374 of 5650 messages
Chat Pages: Latest  142  141  140  139  138  137  136  135  134  133  132  131  Older
DateSubjectAuthorDiscuss
22/2/2017
08:13
So funding at max £26m all convertible to shares plus 20% warrants looks like massive dilution(bearing in mind market cap of £54m) as funding drawdown will be required immediately.
twirl
22/2/2017
07:51
First good news in a while. I doubt funding would be easy to get without providing some evidence of your progress even if they are cautiously drip feeding it. I however am remaining out until after the forthcoming meeting where I expect or at least hope the bod will put the answers to some questions which have been brushed under the carpet for sometime now.
werty5
22/2/2017
07:36
Death spiral funding?
someuwin
20/2/2017
21:47
Ok thanks. Probably a glitch with the barclays platform, would not be the first time.
seans66
20/2/2017
18:45
Yes seans, I have the same entry in my account, and I wondered what it was. If it doesn't disappear I'll phone and ask them about it.
vatnabrekk
20/2/2017
17:02
Any investor can attend this meeting.

I am planning to attend. I guess that any market sensitive material in the presentation will not be revealed until after the market are closes on 6th March, with an RSN issued on 7th March.

BTW have anybody had these showing in their investment accounts?

ADVANCED ONCOTHERA DUMMY FRACTIONS

I guess it could be to do with the placing from last year but I am with Barclaysstockbrokers, know them they are just confused!!

seans66
20/2/2017
11:02
I note that the presentations include:
16.50 Roadmap to Production and Conclusions

Can't help thinking this is something that should be announced to shareholders in an RNS, not just divulged to analysts who are allowed to attend.

igbertsponk
20/2/2017
10:43
Lost my rose tinted spectacles. Must dump this one. Cash crunch.
wiseacre
17/2/2017
16:25
Probably that as well. They are not going to attract them to some poky back street venue.
daijavu
17/2/2017
15:11
Customers ? It's Swiss investors with deep pockets they're after, not customers.
igbertsponk
17/2/2017
15:09
AVO have a world beating piece of kit that they are trying to market to the world. Hiding themselves away in some down at heel back street village hall is unlikely to attract the customers they are after.
daijavu
16/2/2017
17:46
"In Zürich, it will take place at the Baur au Lac hotel, Talstrasse 1, 8001,"

-------

Well they're certainly rolling the boat out in Zurich!


The Baur au Lac is one of their finest, and most expensive hotels!

Quite why they have to hold it there instead of a more modest venue is a pertinent question IMO.

This is not exactly being prudent if funds are in short supply!

andy
16/2/2017
09:22
So ramping the stock early March for a placing mid March by the looks of things.
sweet karolina
14/2/2017
10:39
there can only be a very small float in these shares. Nett purchase 12,000 shares this morning has pushed price up nearly 4%. One bit of good news will see these fly
altom
09/2/2017
15:13
You would think that having had to issue all these embarrassing RNS's about directors and dodgy purchases the company would have updated its website ?
Nah, no rush....

Note they thought Dr Powman had 2.2% at end December, he actually must have had more than the declarable 3%.

More ammunition for the company's detractors.

igbertsponk
09/2/2017
14:24
daijavu,

"Evans sold his shares before he left but did not inform AVO until just before he left"

I think the order of evens was that Evans sold his shares without informing anyone and when this was discovered he was booted off the board.

"Dr Plowman bought shares on an unknown date recently and has been made a NED."

The first significant shareholding was bought in Jun so not recent. Had a TR1 been published at the time we would know when and how many shares he has bought / sold since. I have covered the 2 scenarios for why this did not happen, there may be more but one is as charitable as it is possible to be and the other stinks.

I am glad you agree the financial situation is dire, at the moment. I agree it could change for the better or the worse. Does it make sense to appoint more board members who will be taking fees just for being board members and can still chare additional consultancy?

sweet karolina
09/2/2017
13:59
Clearly uncertainty over testing and funding are undermining the confidence of investors.
It would seem likely that an announcement on the latter will come first. IMHO.
Although AVO have advised the new funding would be non dilutive I cannot see loan finance being other than crippling with provisions to wipe out investors if covenants are breached.
If there is a new or existing investor wishing to provide loan funding then their terms would maybe less onerous than banks.
Otherwise we are back to dilution.
Terms of funding will no doubt be affected by inside knowledge on the testing ie how bad are the snags that caused the delay referred to by Sinophi.
The delay in finding such funding as well as the Sinophi reason for cancellation therefore gives rise to concerns I have over testing.

twirl
09/2/2017
13:47
A company who doesn't know who its shareholders are is a company that doesn't care who they are.
Guess at least the doc will get some directors fees to offset his investment loss.

igbertsponk
09/2/2017
13:15
Sweet Karolina. With respect, I think you might be mixing fact and conjecture.

All I know is that AVO has financial problems but that they are attempting to resolve them, Evans and Lebus left but not why, Evans sold his shares before he left but did not inform AVO until just before he left and Dr Plowman bought shares on an unknown date recently and has been made a NED.

Do you actually know more than that or are you guessing?

I am not exactly over the moon about the current financial situation, the lack of a product, the lack of orders and the Sinophi incident but, if all goes well, they may not be important and neither might the things you are talking about. I'm waiting to see.

daijavu
09/2/2017
12:00
Shareholdings can be monitored through examination of the shareholder register. Clearly AVO do not bother to do this or they would have discovered this and the Evans sell out much sooner. Ultimately though it is the responsibility of the individual to inform the company.

It is clear now that the discovery of the shareholding was as part of the process of bringing him onto the board.

There are 2 possible explanations for why he did not inform the company at the time and as his holdings changed. Firstly he was unaware of the requirement to inform - great does not say much about his ability to perform the corporate governance role of a non exec. Secondly he knew but decided to keep quiet as he was in a position where he would get some info. This scenario really does create significant question marks over his suitability for a board position.

Given the rather dire financial situation AVO is in does it really need more non execs on the board? Yes some have left - Evans under a cloud and Lebus seemingly unhappy with how things are being run, but that is not a reason to appoint more board members. It is perfectly possible for the board to get advice from people who are not on the board. Far too many companies waste far too much money appointing far too many non execs for no good reason.

Ultimately though the real question is does this enhance the prospects for the company digging themselves out of the hole they are in or is it just shuffling deck chairs on the Titanic. Certainly looks like deckchair shuffling to me.

sweet karolina
09/2/2017
11:28
I am told that is for the shareholder to notify the company because the company keeps no record of share transactions.

Perhaps someone can advise if that is the case or not.

daijavu
09/2/2017
10:46
The troublesome issue is that it appears AVO only discovered the non disclosure of share dealing because they wanted to appoint him to the Board.
twirl
09/2/2017
09:44
I like the tech, and would love to invest. But don't think the company is being well run. So happy to point this out whilst I watch.
Apologies if you only want to hear the good news, just put me on ignore.

igbertsponk
09/2/2017
09:40
Well said Freddy
euroto
Chat Pages: Latest  142  141  140  139  138  137  136  135  134  133  132  131  Older

Your Recent History

Delayed Upgrade Clock